Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio
Groundbreaking oncology research zongertinib Groundbreaking oncology research zongertinib Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
We get data science We get data science Data scientists and engineers at Boehringer don't have to field the usual ill-conceived questions and comments. Here's their guide on what not to say!
Global Computational Biology & Digital Sciences Global Computational Biology & Digital Sciences Discover how we play a vital role in identifying new drugs and how our work results in breakthrough therapies.
Translational Medicine & Clinical Pharmacology Translational Medicine & Clinical Pharmacology We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.
Biostatistics & Data Science Biostatistics & Data Science Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
Central Data Science Central Data Science Together with our business and IT colleagues, we develop data science-driven solutions, all the way from ideation to product.
Partnership with IBM to accelerate new antibody therapies Partnership with IBM to accelerate new antibody therapies Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development
university-of-medical-excellence-harvard university-of-medical-excellence-harvard A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
Life forward - Boehringer Ingelheim company brand Life forward - Boehringer Ingelheim company brand Life forward - Boehringer Ingelheim unveils its evolved company brand
Trailr2-cdh17-antibody-phase1-trial Trailr2-cdh17-antibody-phase1-trial Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Sales consultant about working with purpose Sales consultant about working with purpose Bok talks about how he found purpose in his career. After his father was diagnosed with cancer, he decided to work as an oncology sales consultant.
BI 764532: DLL3/CD3 T-cell engager BI 764532: DLL3/CD3 T-cell engager BI 764532: DLL3/CD3 T-cell engager
Announcement for Imagine - our new sustainability story hub Announcement for Imagine - our new sustainability story hub Discover Imagine, our sustainability story hub, showcasing how we drive health equity and advance sustainable healthcare solutions for a better future
Working with purpose Working with purpose Colleagues tell their personal stories and what motivates them to contribute towards a better future for generations to come.
BI 764532: DLL3/CD3 T-cell engager | ep-NEC BI 764532: DLL3/CD3 T-cell engager | ep-NEC BI 764532: DLL3/CD3 T-cell engager | ep-NEC
Partnering-with-google-in-quantum-computing Partnering-with-google-in-quantum-computing New cooperation with Google explores the potentials of quantum computing for pharma R&D.
Disentangling fibrosis Disentangling fibrosis Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.